2017 American Transplant Congress
Effect of HLA-DQ Mismatch on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Köln, Germany; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Human leukocyte antigen (HLA)-DQ mismatches are often associated with acute rejection, independent of mismatches at other loci. Previous analysis from the ELEVATE (NCT01114529) study…2017 American Transplant Congress
Impact of Post Kidney Donation Gout on eGFR and Kidney Stones.
Compared to matched non donor controls, living kidney donors have a higher rate of hyperuricemia early post donation (Kasiske,Am J Kidney Dis,2016) and a higher…2017 American Transplant Congress
Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study.
Purpose: High levels of human leukocyte antigen (HLA) mismatches are a key determinant of kidney allograft survival. Here, we present 24-month (M) subanalysis of the…2017 American Transplant Congress
Post-Donation Remaining Donor Kidney Function as Measured by CKD-EPI Formula at 2 Years Correlates and Is Predicted by Remaining Donor Kidney Volume.
Indiana University School of Medicine, Indianapolis
Aim: The aim of our study was to evaluate whether preserved kidney volume correlates with and can predict donor renal function at 2-years post-donation using…2017 American Transplant Congress
Functional Gain in eGFR Among Living Kidney Donors and Its Association with Remaining Kidney Volume.
Indiana University Health, Indianapolis
Background:CT volumes have good correlation with nuclear imaging to measure split renal function. Kidney volume can be a surrogate marker for nephron mass. Our objectives…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
Short-Term Adverse Effects of Early Borderline Changes in Renal Allograft Biopsies.
Department of Medicine and Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
Background: The short and long-term impact of borderline changes noted on renal allograft biopsies remains unclear.Methods: A total of 379 patients underwent renal transplantation at…2017 American Transplant Congress
Predicting Residual Renal Compensation in Living Kidney Donors Post-Donation.
Ohio State University College of Medicine, Columbus, OH
In living kidney donors it is well established that post-donation the remaining kidney undergoes functional hypertrophy; resulting in a 20% – 40% in increase in…2017 American Transplant Congress
Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).
MPA or mammalian target of rapamycin inhibitors (mTORi [EVR or SIR]) in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine) are used for maintenance…2017 American Transplant Congress
Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Llobregat Catalunya, Spain; 2Novartis Pharma AG, Basel, Switzerland
Purpose: The development of donor-specific antibody (DSA) is a known risk factor for poor graft outcomes after kidney transplantation (KTx). Previous analysis of the ELEVATE…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 27
- Next Page »